Scholarlink

<p>Pharmacotherapy of polycystic ovary syndrome (PCOS) as part of a&#xa0;multimodal treatment concept is challenging due to off-label use and other PCOS-specific considerations. The choice of medication—ranging from oral contraceptives, metformin, and antiandrogens to treatments addressing sequelae and comorbidities—is taken in shared decision-making with the affected woman, balancing substance-specific benefits and side effects. The determination of target goals takes the severity of symptoms, psychological distress, and the preferences of the woman with PCOS into account but also considers the long-term risks of PCOS sequelae and comorbidities such as obesity, diabetes, atherosclerotic cardiovascular disease, and metabolic dysfunction-associated liver disease. In a&#xa0;holistic approach, the treatment concept tailored in interprofessional collaboration should equally address the gynecological and internal medicine facets of PCOS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmakotherapie des PCOS aus internistischer Sicht

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Young Hee Lee-Barkey,
  • Bernd Stratmann,
  • Jasmin M. Klose,
  • Susanne Tan

摘要

Pharmacotherapy of polycystic ovary syndrome (PCOS) as part of a multimodal treatment concept is challenging due to off-label use and other PCOS-specific considerations. The choice of medication—ranging from oral contraceptives, metformin, and antiandrogens to treatments addressing sequelae and comorbidities—is taken in shared decision-making with the affected woman, balancing substance-specific benefits and side effects. The determination of target goals takes the severity of symptoms, psychological distress, and the preferences of the woman with PCOS into account but also considers the long-term risks of PCOS sequelae and comorbidities such as obesity, diabetes, atherosclerotic cardiovascular disease, and metabolic dysfunction-associated liver disease. In a holistic approach, the treatment concept tailored in interprofessional collaboration should equally address the gynecological and internal medicine facets of PCOS.